Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas

Cancer Letters

Volumn 248, Issue 2, 2007, Pages 186-191

  Meister, Michael ^a   Schirmacher, Peter ^b   Dienemann, Hendrik ^a   Mechtersheimer, Gunhild ^b   Schnabel, Philipp A ^b   Kern, Michael A ^b   Herpel, Esther ^b   Xu, Elizabeth C ^a   Muley, Thomas ^a   Thomas, Michael ^a   Rieker, Ralf J ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

EGFR; Mutation; Thymic carcinoma; Thymoma

Indexed keywords

AMINO ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMOMA; THYMUS CANCER;

AGED; AGED, 80 AND OVER; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; THYMOMA; THYMUS NEOPLASMS;

EID: 33847318214     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.07.003     Document Type: Article

References (33)

1. In: Rosai J.., and Sobin L.H. (Eds). Histological Typing of Tumors of the Thymus. World Health Organization. International Histological Classification of Tumours (1999), Springer Verlag, Heidelberg
2. In: Travis W.D., Brambilla E., Müller-Hermelink H.K., and Harris C.C. (Eds). World Health Organization Classification of Tumours. Pathology and genetics of tumors of the Lung, Pleura, Thymus and Heart (2004), IARC Press, Lyon, France
3. Strobel P., Marx A., Zettl A., and Muller-Hermelink H.K. Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg. Today 35 (2005) 805-811
4. Rieker R.J., Hoegel J., Morresi-Hauf A., Hofmann W.J., Blaeker H., Penzel R., and Otto H.F. Histologic classification of thymic epithelial tumors: comparison of established classification schemes. Int. J. Cancer 98 (2002) 900-906
5. Kim D.J., Yang W.I., Choi S.S., Kim K.D., and Chung K.Y. Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review. Chest 127 (2005) 755-761
6. Giaccone G. Treatment of malignant thymoma. Curr. Opin. Oncol. 17 (2005) 140-146
7. Strobel P., Hartmann M., Jakob A., Mikesch K., Brink I., Dirnhofer S., and Marx A. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N. Engl. J. Med 350 (2004) 2625-2626
8. R.J. Rieker, S. Joos, G. Mechtersheimer, H. Blaeker, P.A. Schnabel, A. Morresi-Hauf, E. Hecker, M. Thomas, H. Dienemann, P. Schirmacher, M.A. Kern, COX-2 up-regulation in thymomas and thymic carcinomas, Int. J. Cancer (2006) July 5; [Epub ahead of print].
9. A. Kurup, M. Burns, S. Dropcho, W. Pao, P.J. Loehrer, Phase II study of gefitinib treatment in advanced thymic malignancies. Presentated at the ASCO, Annual Meeting (2005) http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=30129.
10. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
11. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
12. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., and Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101 (2004) 13306-13311
13. Masaoka A., Monden Y., Nakahara K., and Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 48 (1981) 2485-2492
14. Tatusova T.A., and Madden T.L. BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences. FEMS Microbiol. Lett. 174 (1999) 247-250
15. Hayashi Y., Ishii N., Obayashi C., Jinnai K., Hanioka K., Imai Y., and Itoh H. Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch. 426 (1995) 43-50
16. Gilhus N.E., Jones M., Turley H., Gatter K.C., Nagvekar N., Newsom-Davis J., and Willcox N. Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen. J. Clin. Pathol. 48 (1995) 447-455
17. Pescarmona E., Pisacane A., Pignatelli E., and Baroni C.D. Expression of epidermal and nerve growth factor receptors in human thymus and thymomas. Histopathology 23 (1993) 39-44
18. Ionescu D.N., Sasatomi E., Cieply K., Nola M., and Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 103 (2005) 630-636
19. Yang S.H., Mechanic L.E., Yang P., Landi M.T., Bowman E.D., Wampfler J., Meerzaman D., Hong K.M., Mann F., Dracheva T., Fukuoka J., Travis W., Caporaso N.E., Harris C.C., and Jen J. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin. Cancer Res. 11 (2005) 2106-2110
20. Janne P.A., Engelman J.A., and Johnson B.E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol. 23 (2005) 3227-3234
21. Ford A.C., and Grandis J.R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25 (2003) 67-73
22. Pfister D.G., Su Y.B., Kraus D.H., Wolden S.L., Lis E., Aliff T.B., Zahalsky A.J., Lake S., Needle M.N., Shaha A.R., Shah J.P., and Zelefsky M.J. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J. Clin. Oncol. 24 (2006) 1072-1078
23. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., and Ang K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 (2006) 567-578
24. Blackburn C.C., and Manley N.R. Developing a new paradigm for thymus organogenesis. Nat. Rev. Immunol. 4 (2004) 278-289
25. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A.C., Gumerlock P., Bunn Jr. P.A., Franklin W.A., Crowley J., and Gandara D.R. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 23 (2005) 6838-6845
26. Cappuzzo F., Hirsch H.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., Ludovini V., Magrini E., Gregorc V., Doglioni C., Sidoni A., Tonato M., Franklin W.A., Crino L., Bunn Jr. P.A., and Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97 (2005) 643-655
27. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., Yamamoto S., Nokihara H., Yamamoto N., Sekine I., Kunitoh H., Shibata T., Sakiyama T., Yoshida T., and Tamura T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 6829-6837
28. Huh Y.H., Kim S.H., Kim S.J., and Chun J.S. Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes. J. Biol. Chem. 278 (2003) 9691-9697
29. Kulkarni S., Rader J.S., Zhang F., Liapis H., Koki A.T., Masferrer J.L., Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7 (2001) 429-434
30. Pai R., Nakamura T., Moon W.S., and Tarnawski A.S. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J. 17 (2003) 1640-1647
31. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., and Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8 (2002) 289-293
32. Chen Z., Zhang X., Li M., Wang Z., Wieand H.S., Grandis J.R., and Shin D.M. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin. Cancer Res. 10 (2004) 5930-5939
33. Zhang X., Chen Z.G., Choe M.S., Lin Y., Sun S.Y., Wiean H.S., Shin H.J., Chen A., Khuri F.R., and Shin D.M. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin. Cancer Res. 11 (2005) 6261-6269